Method for the use of orally administered 13-cis-retinoic acid i

Details Method for the use of orally administered 13-cis-retinoic acid i Method for the use of orally administered 13-cis-retinoic acid i

1980-08-05

1982-03-30

Schenkman, Leonard

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Recombinant or stably-transformed bacterium encoding one or...

424344, A61K 3120

Patent

active

043224385

ABSTRACT:
In a method of alleviating nodulocystic and conglobate acne in humans by the oral administration of 13-cis-retinoic acid, the improvement comprising: administering the 13-cis-retinoic acid in a high dosage of from 1.0 to 2.0 mg/kg/day for from 2 to 4 weeks; and reducing the amount of 13-cis-retinoic acid to a low dosage of from 0.25 to 0.5 mg/kg/day for a period of from 12 to 14 weeks, so that the total treatment period is about 16 weeks.

REFERENCES:
Strauss et al., J. Invest. Dermatol., 70:228; 4-1978.
Gunby-J.A.M.A., 240:7,610, 8/18/78.
Investigative Drug Brochure, Ro-4-3780, (Hoffman LaRoche, Inc.), 2-1978.
New England Journal of Medicine, vol. 300, No. 7, pp. 329-333 & 359-360, (2-1979).
J.A.M.A., vol. 240, No. 7, p. 610, (8-1978).
Demratologica, 157 (Suppl. 1): 11-12, (1978).
Ophthalmology 85:35, (7-1978).

Affiliated with

Also associated with

Rating

Method for the use of orally administered 13-cis-retinoic acid i does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for the use of orally administered 13-cis-retinoic acid i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the use of orally administered 13-cis-retinoic acid i will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-382629